Related Experiment Videos
Development of new anti-cancer drugs
Abstract:
In the first award lecture of the European Society of Medical Oncology (ESMO) the topic of new drug development and the role of the European Organization for Research and Treatment of Cancer (EORTC) was highlighted. New aspects in each of the drug development steps are discussed: acquisition, screening, formulation, toxicology and phase I studies. In the search for new compounds to treat human solid tumors it is proposed to use human tumors as xenografts in primary screening. Phenomena related to doxorubicin resistance are presented together with a new approach to circumvent this in the clinic. The value of biochemical modulation is discussed, exemplified by the combination of 5-fluorouracil and uridine. The complexity of the biological response modifiers and the importance of evaluating them adequately in the clinic is stressed. The EORTC has recently decided on requirements for the minimum toxicology for phase I trials of a new cytostatic drug in order to ensure safe and rapid evaluation of new anti-cancer compounds. The therapeutic intents of phase I studies are questionable and therefore the main goals of these studies to be reached quickly; possibly supported by a pharmacokinetic rational.
Insights
This lecture highlights new drug development strategies and the European Organization for Research and Treatment of Cancer (EORTC) role. It covers xenografts, drug resistance, and optimizing early-phase clinical trials for cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- The European Society of Medical Oncology (ESMO) award lecture focused on advancing cancer drug discovery.
- Key stages of drug development, including acquisition, screening, formulation, toxicology, and Phase I studies, were discussed.
Purpose of the Study:
- To review novel approaches in anti-cancer drug development.
- To emphasize the European Organization for Research and Treatment of Cancer's (EORTC) contribution to cancer research.
- To address challenges in drug development, such as drug resistance and clinical trial design.
Main Methods:
- Proposal of using human tumor xenografts for primary drug screening.
- Discussion of biochemical modulation strategies, exemplified by 5-fluorouracil and uridine combination.
- Review of doxorubicin resistance mechanisms and potential clinical circumvention.
Main Results:
- Identified new strategies for acquiring and screening anti-cancer compounds.
- Presented methods to overcome drug resistance and enhance therapeutic efficacy.
- Outlined essential toxicology requirements for Phase I trials of new cytostatic drugs.
Conclusions:
- Optimizing drug development requires innovative screening and resistance management.
- Standardized toxicology assessments are crucial for safe and efficient early-phase cancer drug evaluation.
- Phase I studies should prioritize rapid data acquisition, potentially guided by pharmacokinetic data.